Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Biomedicines
Special Issues
State-of-the-Art Endocrine Cancer Biology and Oncology
share announcement

State-of-the-Art Endocrine Cancer Biology and Oncology

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 618

Special Issue Editor

Dr. Piotr Glinicki

E-Mail Website
Guest Editor
1. EndoLab Laboratory, Centre of Postgraduate Medical Education, Warsaw, Poland
2. Department of Endocrinology, Centre of Postgraduate Medical Education, Warsaw, Poland
Interests: adrenal; neuroendocrine tumor; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Endocrine system tumors are a group of proliferative disorders of endocrine glands that are usually associated with the excessive secretion of hormonally active substances (hormones, biogenic amines, catecholamines, and other substances) or substances that do not have any hormonal activity. These tumors can be benign or malignant; the diagnostics of this group of tumors is complex and often requires very specialized investigations (imaging, biochemical, molecular, etc.). Advanced biochemical tests referred to as ‘-omics’ techniques (steroidomics, metabolomics, lipidomics, proteomics, transcriptomics) and molecular biology, often supported by artificial intelligence, open new possibilities in clinical diagnostics. That is, their introduction into diagnostics creates new diagnostic possibilities concerning various stages of the diagnostic and therapeutic process in patients with endocrine system tumors. Furthermore, novel diagnostic techniques enable research in the field of the basic sciences and are increasingly important in medicine/clinical biology. The study of entire panels of chemical compounds/peptides provides a range of important information, the analysis of which in relation to clinical data enables the completion of often advanced clinical diagnostics.

With this, this Special Issue invites original or review papers on research into the diagnostics and biology of endocrine gland tumors. We look forward to your contributions.

Dr. Piotr Glinicki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thyroid and parathyroid tumors
  • adrenal tumors (hormonally active and inactive, ACC)
  • neuroendocrine tumors (NEN)
  • pituitary neuroendocrine tumors (PiNETs)

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 932 KiB  
Article
Implication of p16 Promoter Methylation, the BRAFV600E Mutation, and ETS1 Expression Determination on Papillary Thyroid Carcinoma Prognosis and High-Risk Patients’ Selection
by Stefana Stojanović Novković, Sonja Šelemetjev, Milena Krajnović, Ana Božović, Bojana Kožik, Uršula Prosenc Zmrzljak and Tijana Išić Denčić
Biomedicines 2025, 13(7), 1583; https://doi.org/10.3390/biomedicines13071583 - 27 Jun 2025
Viewed by 457
Abstract
Background/Objectives: Papillary thyroid carcinoma (PTC) is the most common malignancy of the endocrine system, characterized by various molecular alterations. This study evaluates the relationship between p16 promoter methylation status, BRAFV600E mutation presence, and ETS1 (E26 transformation-specific) expression, aiming to better understand their [...] Read more.
Background/Objectives: Papillary thyroid carcinoma (PTC) is the most common malignancy of the endocrine system, characterized by various molecular alterations. This study evaluates the relationship between p16 promoter methylation status, BRAFV600E mutation presence, and ETS1 (E26 transformation-specific) expression, aiming to better understand their clinical significance and to enhance the risk stratification of PTC patients. Methods: p16 promoter methylation was analyzed by methylation-specific PCR (MSP), BRAFV600E by mutant allele-specific PCR amplification (MASA), ETS1 mRNA expression by quantitative PCR (qPCR), ETS1 protein expression by immunohistochemistry (IHC), and Western blot. All tested factors were further associated with the occurrence of unfavorable clinicopathological data of the patients. Results: While p16 methylation did not correlate with adverse clinical parameters or BRAFV600E mutation presence, it was significantly associated with the increased ETS1 mRNA levels. Combined p16 methylation with high ETS1 protein levels was significantly associated with advanced pT and pTNM stages. BRAFV600E-mutated PTC cases with p16 methylation showed increased mRNA and protein ETS1 expression. Conclusions: Therefore, although p16 methylation could not be used as a standalone prognostic marker, its association with elevated ETS1 levels points to its potential involvement in tumor progression and adverse clinical outcomes, particularly in BRAFV600E-mutated PTCs. Deeper insights into these interactions may enhance PTC prognosis and the selection of high-risk patients. Full article
(This article belongs to the Special Issue State-of-the-Art Endocrine Cancer Biology and Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop